Logo

IMNM

Immunome, Inc.

IMNM

Immunome, Inc. • NASDAQ
$18.42 ▼ -1.13% (-0.21)
Market Cap $1.69 B
52w High $19.16
52w Low $5.15
Dividend Yield 0%
P/E -6.22
Volume 275.44K
Outstanding Shares 91.71M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $10.945M ▼ $-57.457M ▼ 0% ▲ $-0.65 ▼ $-56.868M ▼
Q2-2025 $4.015M ▲ $49.773M ▲ $-43.397M ▼ -1.081K% ▲ $-0.5 ▲ $-45.758M ▼
Q1-2025 $2.926M ▲ $47.562M ▼ $-41.64M ▲ -1.423K% ▲ $-0.52 ▲ $-43.91M ▲
Q4-2024 $2.738M ▼ $85.708M ▲ $-80.249M ▼ -2.931K% ▼ $-1.28 ▼ $-55.003M ▼
Q3-2024 $2.91M $53.432M $-47.1M -1.619K% $-0.78 $-43.245M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $272.639M ▲ $299.377M ▲ $35.458M ▲ $263.919M ▼
Q2-2025 $268.036M ▼ $296.29M ▼ $27.02M ▼ $269.27M ▼
Q1-2025 $317.323M ▲ $342.693M ▲ $35.567M ▼ $307.126M ▲
Q4-2024 $217.303M ▼ $240.241M ▼ $59.076M ▲ $181.165M ▼
Q3-2024 $240.13M $256.898M $41.992M $214.906M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-57.457M ▼ $-40.51M ▲ $123.884M ▲ $45.389M ▲ $128.763M ▲ $-41.626M ▲
Q2-2025 $-43.397M ▼ $-49.401M ▲ $-64.171M ▼ $-55K ▼ $-113.627M ▼ $-50.306M ▲
Q1-2025 $-41.64M ▲ $-53.055M ▼ $5.089M ▼ $162.228M ▲ $114.262M ▲ $-56.72M ▼
Q4-2024 $-80.249M ▼ $-42.06M ▼ $9.758M ▼ $20.085M ▲ $-12.217M ▼ $-43.435M ▼
Q3-2024 $-47.1M $-34.167M $24.098M $305K $-9.764M $-35.706M

Five-Year Company Overview

Income Statement

Income Statement Immunome is still a pre-commercial biotech company, so it effectively has no product revenue yet. Reported sales are tiny and mainly reflect collaboration or other non-recurring items, not a commercial business. Operating losses have widened over time as the company has stepped up spending on research, clinical trials, and corporate infrastructure. Net losses and loss per share remain substantial, which is typical for a clinical-stage biotech that is building a pipeline well before any drugs reach the market. Profitability will depend entirely on the success and timing of future approvals or partnership milestones, both of which are uncertain.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and other liquid assets, with very little in the way of physical assets or debt. Cash and total assets have grown in the most recent period, likely reflecting fund-raising activities or the impact of transactions like the Morphimmune merger. Equity has increased alongside assets, suggesting the company is financing itself mainly through issuing shares rather than borrowing. The absence of financial debt reduces interest burden but means existing shareholders bear most of the risk and dilution associated with funding ongoing losses.

Cash Flow

Cash Flow Immunome consistently uses cash in its operations, reflecting spending on R&D, clinical trials, and overhead without offsetting revenue. Operating and free cash outflows have grown more negative recently as the company has accelerated development efforts and modestly increased capital spending. This pattern is normal for a clinical-stage biotech but underscores a key risk: the company depends on external financing, milestone payments, or partnerships to sustain its programs. The pace of cash burn relative to available cash will be an important factor to monitor, especially if trial timelines extend or results are mixed.

Competitive Edge

Competitive Edge Immunome operates in a very crowded and fast-moving oncology space, but it has carved out a differentiated position. Its platform focuses on learning directly from human immune responses to tumors, aiming to find new and more relevant targets than traditional discovery methods. The leadership team brings deep experience from successful antibody-drug conjugate (ADC) companies, which can be a real advantage in design, development, and partnering. Collaborations, such as the discovery partnership with AbbVie, provide third-party validation and some funding. At the same time, the company competes against large, well-funded pharma and biotech players, and any given cancer target may face multiple rival programs, so maintaining a durable edge is not guaranteed.

Innovation and R&D

Innovation and R&D Innovation is the core of Immunome’s story. The company’s discovery engine mines memory B cells to uncover novel cancer targets, which could lead to first-in-class therapies if the science translates well in humans. It is building a diversified portfolio across ADCs, radioligand therapies, and small molecules, reducing reliance on any single program. Key assets include a Phase 3 oral therapy for desmoid tumors, an advanced ADC against ROR1 using a novel payload designed to tackle resistance, and an early radioligand program against FAP, plus several earlier ADC candidates. The pipeline is still largely in clinical or preclinical stages, so scientific and regulatory risk remains high, but the breadth of modalities and targets suggests a strong commitment to long-term R&D and platform leverage.

Summary

Immunome is an early-stage oncology biotech with minimal revenue, significant operating losses, and a business model built around high-risk, high-reward drug development. Its financials reflect a typical clinical-stage profile: growing R&D spend, negative cash flow, and reliance on equity financing rather than debt. The balance sheet currently shows a solid cash base and no borrowings, but ongoing development will continue to consume cash until meaningful partnership income or product sales emerge. Strategically, the company’s strengths lie in a distinctive discovery platform, a seasoned ADC-focused leadership team, and a diversified pipeline that addresses both niche and broader cancer opportunities. The main uncertainties relate to clinical trial outcomes, regulatory approvals, competitive responses, and the need for future capital, all of which will shape whether the current scientific promise translates into durable commercial value.

NEWS

November 25, 2025 · 8:00 AM UTC

Immunome to Present at Upcoming Investor Conferences

Read more

November 6, 2025 · 4:05 PM UTC

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 4, 2025 · 4:05 PM UTC

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 31, 2025 · 11:51 AM UTC

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Read more

October 23, 2025 · 12:00 PM UTC

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Read more